ERBB2 and neoplasm: Mice were inoculated with HER2+ tumors and treated with a HER2-based DNA vaccine, encoding the extracellular and transmembrane regions of HER2 as well as GM-CSF, which upon secretion would help to recruit antigen-presenting cells and thus enhance tumor-specific T cell priming.